E-mail

E-mail a Wiley Online Library Link

Maurie Markman The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy Cancer 117

Version of Record online: 5 OCT 2010 | DOI: 10.1002/cncr.25459

It is rational to suggest that the decision to alter treatment in advanced ovarian cancer should be based on the totality of evidence that the disease is worsening, on patient tolerability of the therapy, and on a determination that the current regimen is providing no benefit or unacceptably limited benefit to the specific individual. Knowledge of an objective measure of “progression” should play an important, but not a singular, role.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH